Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

about

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment Current status of theranostics in prostate cancer.Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.

P2860

Q41475179-D136A542-3058-4B8D-B524-6AC7FA49167F Q47241139-CBF9F6FC-F680-475E-A2C1-D2D7A3C57A88 Q53682227-7EFAEF88-29A3-4C0D-B784-10AB3B5245C5

P2860

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

Item

http://www.wikidata.org/entity/Q37390666

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

@en

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.

@nl

type

Item

label

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

@en

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.

@nl

prefLabel

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

@en

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer.

@nl

P1476

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

@en

P2093

Andrei H Iagaru

http://www.w3.org/2001/XMLSchema#string

Erik Mittra

http://www.w3.org/2001/XMLSchema#string

Hossein Jadvar

http://www.w3.org/2001/XMLSchema#string

Patrick M Colletti

http://www.w3.org/2001/XMLSchema#string

P2860

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

Cancer statistics, 2016

Alpha emitter radium-223 and survival in metastatic prostate cancer

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.

Skeletal PET with 18F-fluoride: applying new technology to an old tracer.

P304

19S-24S

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.115.170746

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

Suppl 3

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27694165

http://www.w3.org/2001/XMLSchema#string

P932

5093914

http://www.w3.org/2001/XMLSchema#string

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

about

P2860

P2860

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932